Decree No. 275 / 2010 Coll.
Decree amending Decree No. 473 / 2008 Coll., on an epidemiological vigilance system for selected infections
Valid
Order
Effective from 12.10.2010
Text versions:
12.10.2010
27.09.2010
Contents
Čl. I
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 8
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. II
Zobrazeno prvních 200 z celkem 667 ustanovení tohoto předpisu.
Zobrazit celý předpis →
Pro stažení celého znění použijte tlačítko Stáhnout výše.
275
DECLARATION
of 13 September 2010
amending Decree No. 473 / 2008 Coll., on an epidemiological vigilance system for selected infections
According to Article 108 (1) of Act No. 258 / 2000 Coll., on the Protection of Public Health and on the Amendment of Certain Related Acts, as amended by Act No. 274 / 2001 Coll., Act No. 320 / 2002 Coll., Act No. 274 / 2003 Coll., Act No. 392 / 2005 Coll., Act No. 222 / 2006 Coll. and Act No. 110 / 2007 Coll., ("the Act ') for the implementation of Section 75a paragraphs 1 and 4 of the Act:
Decree No. 473 / 2008 Coll., on an epidemiological vigilance system for selected infections, is amended as follows:
1. In Article 3, the current text becomes paragraph 1 and the following paragraph 2 is added:
"(2) The scope of the data and the procedure provided for in Articles 1 (a) to (c) shall be further adjusted where:
(a) West Nile fever Annex 15 to this Decree;
(b) by enterohaemorrhagic Escherichia coli (EEC) Annex No 16 to this Decree;
(c) Viral hepatitis A Annex 17 to this Decree;
(d) Viral hepatitis B Annex 18 to this Decree;
(e) Viral hepatitis C Annex 19 to this Decree;
(f) Chlamydia trachomatis Annex No 20 to this Decree,
(g) invasive pneumococcal diseases Annex 21 to this Decree;
(h) campylobacteriosis Annex No 22 to this Decree;
(i) Lyme disease Annex No 23 to this Decree;
(j) belt herpes Annex 24 to this Decree;
(k) rotavirus infections Annex 25 to this Decree;
(l) salmonella Annex No 26 to this Decree,
(m) obtained or congenital syphilis Annex No 27 to this Decree;
(n) tick encephalitis Annex No 28 to this Decree;
(o) chickenpox (varicella) Annex 29 to this Decree. ';
2. In Paragraph 4, "14 'is replaced by" 29'.
3. In Annex 1, point 1.2, the word "(Syphilis) 'is added after the word" Reception'.
4. In Annex 1, point 1.4, the words "Rotavirus infections' shall be added at the end of the text.
5. In Annex No 1, the following is added at the end of the text in point 1.5.3:
"Lyme disease
Tick encephalitis'.
6. The following point 1.5.5 is inserted after point 1.5.4 of Annex 1:
"1.5.5. Other diseases
Chicken pox
Belt herpes. "
7. The following Annexes 15 to 29 are inserted after Annex 14:
"Annex No 15 to Decree No 473 / 2008 Coll.
The epidemiological alert system for West Nile fever virus diseases (WNV)
Clinical definition of disease
1. Clinical image consistent with feverish illness with neurological symptoms, ranging from severe headache and muscle pain to aseptic meningitis or encephalitis, with an incubation period of 2 to 6 days, within a maximum range of 2-15 days, to exposure that is conditional on mosquito ticks, rarely sucking hyalomma, or transferring human agent to human transplant, transfusion or transplacental. The transfer of WNV from human to human to blood to tissue is not considered real. The majority of the diseases are administered inappropriately, approximately 20% of cases are manifested by maculopapular rash and lymphodenopathy, and the central nervous system is affected by less than 1% of clinical manifestations. During the typical course of the disease it lasts 2 to 7 days.
2. Viraemia peaked at the time of first symptoms, gradually decreasing virus concentrations to insignificant values within the next 4 to 6 days. The immunity after the disease is expected to last for life, but a gradual decrease in titre of specific protective antibodies has been demonstrated.
Laboratory diagnostics
1. Proof of specific antibody response (serum, liquor).
2. Detection of nucleic acid in blood or liquor.
Laboratory criteria for probable case:
1. Determination of IgM antibodies against WNV in serum by ELISA test.
2. Determination of IgG antibodies against WNV in serum by ELISA test.
3. Determination of serum WNV antibodies by HIT inhibition test.
Laboratory criteria for a confirmed case:
1. Proof of the presence of specific IgM antibodies against WNV in CSF.
2. Isolation of WNV from blood or cerebrospinal fluid.
3. Detection of WNV nucleic acid in blood or CSF.
4. Positive virus neutralizing test.
The biological material collected (serum or liquor) shall be sent to the national reference laboratory for arbovirus by the relevant medical establishment.
Laboratory results should always be interpreted according to the condition of possible vaccination against certain diseases caused by other flaviviruses, or the recent diseases reported by these infections (tick encephalitis, yellow fever, Japanese B encephalitis, dengue).
Epidemiological criteria
At least one of the following epidemiological links:
1. Transfer from animal to human (residence, visit or exposure of mosquito ticks in an area with endemic WNV in horses and birds, or places with extreme mosquito multiplication, especially in relation to flooding, exceptionally transfer by tick-sucking)
2. Transfer from human to human (transplantation, blood transfusion, or transplacental).
Classification of a disease case
A. Possible: Unable to use.
B. Likely: Any person meeting the clinical criteria and at least one of the following two situations:
1. epidemiological link,
2. at least one of the laboratory criteria for a probable case.
C. Confirmed: Any person meeting the clinical criteria and at least one of the laboratory criteria for a confirmed case.
Data collection and reporting
1. A person providing care 1) who diagnoses WNV in accordance with the criteria in Articles 1 to 3 shall report to the public health authority confirmed and likely cases of or deaths from the disease. In view of the global changes in the geographical distribution of the disease vector, data relating to the relevant travel history of the affected person and data which may be related to the possible inter-human transmission of the disease agent (transplantation, transfusion, or transplacental transmission) should be carefully collected and reported.
2. The local competent public health authority shall ensure an immediate transmission of information on a confirmed case of WNV infection to all transfusions of the transfusions service in a pre-agreed manner, while informing the Ministry of Health.
3. The Ministry of Health will ensure, on the basis of reports received through the European Commission's Rapid Alert System (EWRS) and other similar systems, the transmission of information on the current epidemiological situation in the presence of human WNV diseases abroad, all the workplaces of the transfusion service and public health authorities in the Czech Republic.
Transfusion service activities
1. Transfusion services shall ensure that:
(a) exclusion from donating full blood and blood components to all persons residing in an area with ongoing transfer of WNV to humans for 28 days after leaving such areas3);
(b) in the cases indicated, tests for the presence of WNV nucleic acids, which have been identified as whole blood and blood components.
2. The Society for Transfusion Medicine of the Czech Medical Society Jan E. Purkyně will ensure the publication of information on the current epidemiological situation in the occurrence of human cases of WNV disease abroad according to reports sent via the Ministry of Health and the State Institute for Drug Control on its website.
Epidemiological investigation on suspected occurrence of WNV
The person providing care (1) who has expressed suspicion of WNV infection shall collect the biological material for the etiological agent laboratory certificate and arrange for the transport of the collected material to the National Reference Laboratory for Arbovirus. The national reference laboratory for arbovirus shall report the results as agreed in writing or by telephone to the person providing the care 1) and the relevant anti-epidemic department of the public health authority.
Anti-epidemic measures in the outbreak of WNV
1. Reporting of WNV as referred to in Article 5.
2. Ensure the collection of biological material to verify the diagnosis and transport it to the National Reference Laboratory for Arbovirus.
3. Anti-epidemic measures within the scope of Articles 2, 5, 6 and 7 shall be carried out on the occurrence or suspicion of all WNV cases.
Příloha č. 16
Annex No 16 to Decree No 473 / 2008 Coll.
The epidemiological vigilance system of infections caused by enterohaemorrhagic Escherichia coli (EEC)
Clinical definition of disease
1. Clinical image consistent with EHEC infection is diarrhoea, often bloody, and abdominal cramps, usually without temperature or only with low temperature (below 38 ° C). The disease may be complicated by haemolytic-uremic syndrome (HUS, dg. D59.3). Shiga toxin (Verotoxins): Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) are the main role of EHEC infection pathogenesis.
2. The incubation period is 2 to 8 days. Depending on the size of the infectious dose, which is very low (in the O157: H7 strains 10-100 bacteria are reported), the age and susceptibility of the individual. The most risky groups of patients are children under the age of 5 and persons over 60.
3. The disease lasts between 5 and 6 days for easier cases, in case of systemic complications (HUS), the disease lasts up to a number of weeks.
Laboratory diagnostics
1. Isolation and serotyping of Escherichia coli strains (slide agglutination O, H antigens).
2. Shiga (Verotoxins) card (latex agglutination, ELISA and others).
3. Detection of genes encoding the production of Shiga toxins 1 and 2 and their subcharacterisation.
4. Detection of other virulence factors of EHEC strains: detection of genes for adhezin Intimine (eae) and EHEC haemolysin (EHEC-hlyA) by PCR.
5. Confirmation of O and H antigens by genetic methods.
6. The method of restriction analysis (PFGE) for the genetic detection of identical strains in the epidemiological context.
7. Immunological determination of lipopolysaccharide (LPS) antibodies in serum by immunoblotting methods, passive haemagglutination, ELISA.
The examination is carried out from a stool sample at the beginning of the disease, otherwise the probability of finding etiological agents in the material is rapidly decreasing. In case of failure of classical cultivation, it is appropriate to use the method of immunomagnetic separation in selected laboratories (National Reference Laboratory for Escherichia coli and Shigels) for the detection of EHEC strain from stool, which must be stored for this examination at minus 70 ° C.
Epidemiological criteria
At least one of the following epidemiological links:
1. Transfer from human to human
2. Exposure to a common source
3. Transfer from animal to human
4. Exposure to contaminated foods or drinking water
5. Exposure to environmental resources
Classification of a disease case
A. Possible: Unable to use.
B. Likely: Case with clinical signs that have an epidemiological link or laboratory confirmed isolate without clinical signs of disease.
C. Confirmed: Clinically relevant case, which is laboratory confirmed by EHEC isolation.
Data collection and reporting
The person providing care 1) who diagnoses the EHEC disease according to the criteria in Articles 1 to 3 shall report to the public health authority a probable or confirmed case or death of EHEC disease.
Epidemiological investigations when an EEC is suspected
1. A person providing care 1) who has expressed a suspicion of EHEC disease will arrange for the removal of the stool and its immediate transport to the investigating microbiological laboratory. The microbiological laboratory shall report the results to the person providing care (1) and to the relevant anti-epidemic department of the public health authority. In case of capture of suspected EHEC strains, in particular the O157, O26, O111, O103 and O145 serogroups, the laboratory shall immediately send the strains to the National Reference Laboratory for Escherichia coli and shigels of the State Health Institute. The national reference laboratory shall carry out confirmation of strains, detection of Shiga toxins as well as other EHEC virulence factors and report back to the treating physician, the relevant anti-epidemic department of the public health authority and the microbiological laboratory.
2. The relevant anti-epidemic separation of the public health authority shall ensure an epidemiological investigation in all cases. The investigation is mainly aimed at a detailed search for the source of the disease, the route of transmission of the disease, and other cases in the outbreak, the clinical form of the disease and possible deaths, the verification of the proper collection of biological material for the laboratory evidence of etiology, and, where appropriate, the active provision of biological material. These investigations must be initiated immediately after the EHEC infection certificate in the first case (case index).
Anti-epidemic measures in the EHEC outbreak
1. Reporting of EEC disease as referred to in Article 5.
2. Ensuring the collection of biological material for laboratory testing.
3. Isolation of the patient, in more difficult cases, necessary hospitalisation under another legislation4).
4. Active search for all contacts and microbiological examination of their stool sample, requiring serotyping of Escherichia coli. For strains of serotype identical to the disease agent, ensure testing of Shiga toxin production.
5. Medical supervision for 8 days after the occurrence of the last disease.
6. Consistent compliance with hygiene measures in food production, including compliance with production technology and good manufacturing practice.
7. Cooperation with the authorities of the State Veterinary Administration and the State Agricultural and Food Inspection in the tracing of vehicle diseases.
Příloha č. 17
Annex No. 17 to Decree No. 473 / 2008 Coll.
The epidemiological vigilance system for viral hepatitis A ("VHA ')
Clinical definition of disease
1. Clinical image consistent with VHA: progressive development of symptoms, especially fatigue, abdominal pain, loss of appetite, occasional nausea and vomiting, along with a symptom of fever, or jaundice, or elevated serum aminotransferase levels.
2. Infectious period: The virus is present in the faeces 1 to 2 weeks before the start of the disease and 1 to 3 weeks after the start of the disease, exceptionally, a period of up to 6 months has been described. The virus is present in the blood in the second half of the incubation period and at the beginning of the disease.
Laboratory diagnostics
At least one of the following criteria:
1. Detection of specific IgM antibodies against VHA.
2. Detection of VHA nucleic acid in serum, plasma or faeces.
3. Detection of VHA antigen in faeces.
Epidemiological criteria
At least one of the following epidemiological links:
1. Transfer from human to human
2. Exposure to a common source
3. Exposure to contaminated foods or drinking water
4. Exposure to environmental resources
Classification of a disease case
A. Possible: Unable to use.
B. Likely: Any person meeting the clinical criteria with an epidemiological link.
C. Confirmed: Any person meeting the clinical and laboratory criteria.
Data collection and reporting
A person providing care 1) who diagnoses VHA disease reports to the public health authority a confirmed case of and deaths from the disease.
Epidemiological investigation if VHA is suspected
The person providing care (1) who has expressed suspicion of VHA disease shall collect biological material for laboratory identification and arrange for its transport to the investigating laboratory. Epidemiological investigations shall be carried out by the public health authority, in particular with a view to identifying the source of infection and the route of transmission.
Anti-epidemic measures in the outbreak of VHA disease
1. Reporting of VHA disease as referred to in Article 5.
2. Ensuring the collection and transport of the patient's biological material and contacts to verify the diagnosis in the appropriate laboratory.
3. Isolation of a sick person, or from a suspected illness, in an infectious ward according to another law2).
4. For persons who have been in contact with the patient, medical supervision shall be performed 50 days after the last contact.
5. The admission of new persons to pre-school children's collectives is prohibited at the time of medical supervision for the presence of VHA, as assessed by the local competent public health authority.
6. Persons in contact with VHA carrying out epidemiological activities shall be excluded from these activities by imposing increased medical supervision for 50 days from the last contact with the patient.
7. The restrictions referred to in paragraphs 4, 5 and 6 shall not apply to persons who have been shown to have overall antibodies and at the same time to the specific IgM antibodies against the VHA virus and to persons who have been shown to have been properly vaccinated against VHA.
8. The competent public health authority will order the scope and method of immunoprophylaxis and, after approval by the main hygienist of the Czech Republic, provide exceptional vaccination in collectives. Following a decision of the local competent public health authority on medical supervision or increased health surveillance, the person providing the care (1) shall ensure that persons in direct contact with the VHA are vaccinated against the VHA.
9. For donors of blood and other biological material5).
Příloha č. 18
Annex No 18 to Decree No 473 / 2008 Coll.
The epidemiological alert system for acute viral hepatitis B (VHB)
Clinical definition of disease
1. Clinical image matching VHB: progressive development of symptoms, especially fatigue, abdominal pain, loss of appetite, occasional nausea and vomiting, along with a symptom of fever, or jaundice, or elevated serum aminotransferase levels.
2. Infection period: all HBsAg positive persons are potentially infectious.
Laboratory diagnostics
Detection of specific IgM antibodies against nucleocapsid antigen (core) VHB.
Epidemiological criteria
Epidemiological link with human to human transmission, especially blood transfer, sexual contact, or vertical transmission.
Classification of a disease case
A. Possible: Unable to use.
B. Likely: Any person meeting the clinical criteria with an epidemiological link.
C. Confirmed: Any person meeting the clinical and laboratory criteria.
Data collection and reporting
Contents
Čl. I
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 8
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. 1
Čl. 2
Čl. 3
Čl. 4
Čl. 5
Čl. 6
Čl. 7
Čl. II
Sign in for notes, favorites and notifications
Regulation Information
| Citation | Decree No. 275 / 2010 Coll., amending Decree No. 473 / 2008 Coll., on the epidemiological vigilance system for selected infections |
|---|---|
| Regulation Type | Order |
| Author | - |
| Collection | Code of Laws |
| Date of Promulgation | 27.09.2010 |
|---|---|
| Effective from | 12.10.2010 |
| Effective until | - |
| Status | Valid |
Legal Areas:
Administrative law
Health
The regulation text is for informational purposes only.
Comments 0